Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Keith Thomas Flaherty, M.D.

Co-Author

This page shows the publications co-authored by Keith Flaherty and Benchun Miao.
Connection Strength

0.694
  1. EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma. Cancer Discov. 2015 Mar; 5(3):274-87.
    View in: PubMed
    Score: 0.154
  2. Evolution of delayed resistance to immunotherapy in a melanoma responder. Nat Med. 2021 06; 27(6):985-992.
    View in: PubMed
    Score: 0.060
  3. A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors. Clin Cancer Res. 2019 11 15; 25(22):6852-6867.
    View in: PubMed
    Score: 0.053
  4. Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy. Mol Syst Biol. 2019 03 11; 15(3):e8323.
    View in: PubMed
    Score: 0.052
  5. Publisher Correction: Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. Nat Med. 2018 Dec; 24(12):1942.
    View in: PubMed
    Score: 0.051
  6. A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. Cell. 2018 11 01; 175(4):984-997.e24.
    View in: PubMed
    Score: 0.050
  7. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. Nat Med. 2018 10; 24(10):1545-1549.
    View in: PubMed
    Score: 0.050
  8. Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma. Clin Cancer Res. 2018 10 01; 24(19):4771-4784.
    View in: PubMed
    Score: 0.048
  9. Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discov. 2018 02; 8(2):196-215.
    View in: PubMed
    Score: 0.047
  10. PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Nature. 2017 10 05; 550(7674):133-136.
    View in: PubMed
    Score: 0.047
  11. A novel multi-CDK inhibitor P1446A-05 restricts melanoma growth and produces synergistic effects in combination with MAPK pathway inhibitors. . 2016 07 02; 17(7):778-84.
    View in: PubMed
    Score: 0.043
  12. MITF Modulates Therapeutic Resistance through EGFR Signaling. J Invest Dermatol. 2015 Jul; 135(7):1863-1872.
    View in: PubMed
    Score: 0.039
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.